BPC-157 reconstitution calculator

BPC-157 — short for Body Protection Compound 157 — is a synthetic peptide originally derived from a sequence found in human gastric juice. It is one of the most widely discussed peptides in the research market, primarily because of its long history in animal studies looking at tissue and connective-tissue contexts.

BPC-157 is supplied as a lyophilized powder in vials rated in milligrams of active peptide. Common vial sizes are 2 mg, 5 mg, and 10 mg. Because typical illustrative doses are well below 1 mg, the dose calculator on this page defaults to micrograms — using mg with a typed value like 0.25 makes decimal-place mistakes much more likely than typing 250 mcg.

Unlike the long-acting GLP-1 peptides on this site, BPC-157 is short-acting and is typically logged on a daily — sometimes twice-daily — cadence in most personal logs. That changes the vial duration math significantly: even a small vial covers many doses on a weekly basis.

BPC-157, or Body Protection Compound 157, is a synthetic peptide fragment corresponding to a 15-amino-acid sequence of a larger protective protein discovered in human gastric juice. Its full primary structure is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. This sequence is notable for its central, proline-rich portion, which grants it unusual structural rigidity. In research literature, this feature is hypothesized to contribute to its observed resistance to enzymatic degradation in the gastrointestinal tract, a factor potentially linked to the oral bioavailability observed in some animal studies.

The origin of this peptide as part of a naturally occurring gastric protein informs the context of its scientific study. Unlike purely synthetic compounds, its structure is derived from a biological system responsible for protecting the stomach lining. This biological context is a key element for researchers examining its various activities in preclinical models. Documenting personal research requires understanding that its properties are studied in relation to its origins as a small, stable fragment of a much larger parent protein.

BPC-157 is studied for its possible effects in tissue and connective-tissue contexts. The mechanistic literature is still developing and there are no peptide-page-appropriate clinical claims to make beyond noting that it remains a topic of active research.

Anyone tracking BPC-157 in a personal log will benefit from pairing the dose history with whatever metric the protocol is targeting — joint comfort ratings, recovery notes, or general wellbeing tracking. As with every peptide, the trend across weeks is what is meaningful, not any single day.

Published research on the mechanisms of BPC-157 frequently centers on its interaction with angiogenesis, the process of forming new blood vessels. Specifically, studies have observed its influence on the Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) signaling pathway. In various research models, the peptide has been documented to modulate the activation of this key receptor. This interaction is often studied in conjunction with the nitric oxide (NO) system, as the VEGFR2 pathway and NO synthesis are closely linked. The scientific inquiry focuses on how BPC-157 might influence these cascades, providing a framework for observing its effects at a molecular level without making clinical claims.

Daily subcutaneous injection is the default cadence in most BPC-157 logs, and twice-daily protocols also appear. Doses are small enough that a U-100 insulin syringe is the standard tool.

Cycling — running BPC-157 for a defined number of weeks, then taking a break — is common in personal logs. Recording the start and stop date of each cycle in the log is what makes the timeline auditable later.

Some users inject BPC-157 close to a target area; others prefer rotating standard subcutaneous sites. Either way, recording the injection site in the log is what surfaces site-rotation patterns over time.

A unique consideration when planning a documentation schedule for BPC-157 is the administration route. While subcutaneous injection is common in peptide research, a significant body of preclinical literature on BPC-157 also explores oral administration. This dual-route exploration makes it a critical variable to log for accurate personal tracking. If a protocol involves subcutaneous administration, precise dose calculation is necessary. For example, a 5 mg vial reconstituted with 2 mL of bacteriostatic water yields a concentration of 2,500 mcg/mL. A 250 mcg illustrative dose is 0.1 mL or 10 units on a U-100 syringe. This dose would be logged with a daily cadence, explicitly noting the administration route (e.g., 'Subcutaneous, left thigh') to distinguish it from any potential oral use.

The illustrative example on this page assumes a 5 mg vial reconstituted with 2 mL of bacteriostatic water. That produces a concentration of 2.5 mg per mL, or 2,500 mcg per mL. A 250 mcg illustrative dose on that vial is 0.1 mL — exactly 10 units on a U-100 insulin syringe.

Because BPC-157 doses are small, choosing a sensible diluent volume matters. Less BAC water concentrates the solution and reduces the unit count per dose, which can be hard to read accurately at very small unit numbers. More BAC water produces cleaner, easier-to-read draws at the cost of slightly fewer total doses per vial.

The preparation method for BPC-157 can differ based on the administration route being documented, which adds a layer of complexity to the logging process. For subcutaneous injection, the standard procedure involves reconstituting the lyophilized powder with a sterile diluent like bacteriostatic water. However, research models that study oral administration describe a different preparation. In these published studies, the peptide is often dissolved directly into a measured volume of drinking water for consumption. Therefore, a comprehensive tracking log should not only record the dose and route but also the specific preparation method used, as this reflects a fundamental difference in how the compound is prepared for administration.

Lyophilized BPC-157 powder is generally stored refrigerated until reconstitution. The in-use reconstituted vial is typically kept refrigerated and used within several weeks. Marking the reconstitution date directly on the vial avoids the common case of finding an unmarked vial later and not knowing whether it is still in its useful window.

Daily peptides like BPC-157 are where logging discipline matters most: the cadence is high, the doses are small, and the easiest mistake is double-dosing or skipping after losing track of the day. A timestamped dose log removes that ambiguity entirely.

The daily administration cadence often documented for BPC-157 makes meticulous injection site rotation tracking particularly important. Repeated subcutaneous injections at the same anatomical location can lead to palpable changes in the underlying subcutaneous fat tissue, a condition known as lipohypertrophy. To properly monitor for such changes, a detailed site rotation log is invaluable. A simple and effective method is to mentally divide the abdomen into four quadrants (upper-right, lower-right, upper-left, lower-left) and rotate through them systematically. Other potential sites like the deltoids, thighs, and glutes can also be incorporated into the rotation. Accurately recording the date and location of every injection allows an individual to audit their protocol and correlate any observed skin or tissue irregularities with their administration history.